Articles about 'NIHR Bioresource'

Smiling elderly woman speaking to a healthcare worker

Over 20,000 people join search for new dementia treatments

14 May 2024

More than 20,000 volunteers have been recruited to a resource aimed at speeding up the development of much-needed dementia drugs. The cohort will enable scientists in universities and industry to involve healthy individuals who may be at increased risk of dementia in clinical trials to test whether new drugs can slow the decline in various brain functions including memory and delay the onset of dementia.

CamFest Speaker Spotlight: Dr Anna Moore

26 March 2024

Assistant Professor of Child Psychiatry at the University of Cambridge and programme lead, Dr Anna Moore, discusses the NIHR BioResource’s national childhood health research programme, D-CYPHR. The groundbreaking programme is a world first and aims to be the largest ever DNA research programme involving children aged 0-15.

A man sitting on a couch holding his head in his hands

Low iron levels resulting from infection could be key trigger of long COVID

04 March 2024

Problems with iron levels in the blood and the body’s ability to regulate this important nutrient as a result of SARS-CoV-2 infection could be a key trigger for long COVID, new research has discovered.

Largest ever DNA and health research programme for children and young people launches

25 July 2023

Cambridge researchers are helping launch a nationwide study for children and young people to unlock the power of our DNA.

Patient receiving a COVID-19 vaccination

Obesity accelerates loss of COVID-19 vaccination immunity, study finds

11 May 2023

The protection offered by COVID-19 vaccination declines more rapidly in people with severe obesity than in those with normal weight, scientists at the Universities of Cambridge and Edinburgh have found. The study suggests that people with obesity are likely to need more frequent booster doses to maintain their immunity.

Senior woman wearing face mask lying on hospital bed

Cognitive impairment from severe COVID-19 equivalent to 20 years of ageing, study finds

03 May 2022

Cognitive impairment as a result of severe COVID-19 is similar to that sustained between 50 and 70 years of age and is the equivalent to losing 10 IQ points, say a team of scientists from the University of Cambridge and Imperial College London.

Likelihood of severe and ‘long’ COVID may be established very early on following infection

18 January 2021

New research provides important insights into the role played by the immune system in preventing – and in some cases increasing the severity of – COVID-19 symptoms in patients. It also finds clues to why some people experience ‘long COVID’.

Creative rendition of SARS-COV-2 virus particles

Remdesivir likely to be highly effective antiviral against SARS-CoV-2 for some patients

14 December 2020

The drug remdesivir is likely to be a highly effective antiviral against SARS-CoV-2, according to a new study by a team of UK scientists. Writing in Nature Communications, the researchers describe giving the drug to a patient with COVID-19 and a rare immune disorder, and observing a dramatic improvement in his symptoms and the disappearance of the virus.

Over 20,000 people join search for new dementia treatments

CamFest Speaker Spotlight: Dr Anna Moore

Low iron levels resulting from infection could be key trigger of long COVID

Largest ever DNA and health research programme for children and young people launches

Obesity accelerates loss of COVID-19 vaccination immunity, study finds

Cognitive impairment from severe COVID-19 equivalent to 20 years of ageing, study finds

Likelihood of severe and ‘long’ COVID may be established very early on following infection

Remdesivir likely to be highly effective antiviral against SARS-CoV-2 for some patients

Connect with us

Study at Cambridge

About the University

Research at Cambridge